Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading ...

Alumis' Phase 3 ONWARD data show envudeucitinib delivers durable scalp clearance and itch relief through 48 weeks in ...

Alumis plans to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Over ...

Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, palmoplantar, and nail improvements, without new safety signals. Zasocitinib 30 mg ...

Your skin is constantly renewing itself. In healthy skin, new cells are made deep in the epidermis. They slowly move toward the surface, mature along the way, and eventually shed. This process usually ...

If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.

Zasocitinib was 2.5 times more effective than deucravacitinib at helping patients with plaque psoriasis achieve completely clear skin, based on the first head-to-head test.

PRNewswire/ -- (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), ...

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment ...

A two-year Japanese real-world study of 66 patients shows the dual IL-17A and IL-17F inhibitor bimekizumab sustained high ...